Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.
- DOI
- 10.1186/s12879-025-12064-1
- Published
- 2025 Dec 18
- Container
- BMC infectious diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12879-025-12064-1,
title = {Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.},
author = {Shi L and Gao X and Huang L and Gao Z and Li J and Yu B and Fan H and Li G and Wang Y and Li Q and Yuan L and Li C and Mo Z and HPV1003 Study group and Li Shi and Ke Li and Min Ji and Ya-Lin Hu and Ling-Yun Zhou and Xue-Mei Yan and Jing-Jing Chen and Wei Li and Zi-Long Wang and Zhen Huang and Yu-Liang Zhao and Rong-Cheng Li and Yan-Ping Li and Nian-Min Shi and Qiang Lu and Bin He and Shi-Fang Wen and Dong-Zhang Yang and Guo-Gang Liu and Yan-Xia Cai and Wei-Jiang Cui and Jiang-Bing Zheng and Zhan-Bo Geng and Yan-Hua Xie and Yong-Biao Ren and Hai-Song Zhou},
year = {2025},
journal = {BMC infectious diseases},
doi = {10.1186/s12879-025-12064-1},
url = {https://doi.org/10.1186/s12879-025-12064-1}
}RIS
TY - JOUR TI - Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial. AU - Shi L AU - Gao X AU - Huang L AU - Gao Z AU - Li J AU - Yu B AU - Fan H AU - Li G AU - Wang Y AU - Li Q AU - Yuan L AU - Li C AU - Mo Z AU - HPV1003 Study group AU - Li Shi AU - Ke Li AU - Min Ji AU - Ya-Lin Hu AU - Ling-Yun Zhou AU - Xue-Mei Yan AU - Jing-Jing Chen AU - Wei Li AU - Zi-Long Wang AU - Zhen Huang AU - Yu-Liang Zhao AU - Rong-Cheng Li AU - Yan-Ping Li AU - Nian-Min Shi AU - Qiang Lu AU - Bin He AU - Shi-Fang Wen AU - Dong-Zhang Yang AU - Guo-Gang Liu AU - Yan-Xia Cai AU - Wei-Jiang Cui AU - Jiang-Bing Zheng AU - Zhan-Bo Geng AU - Yan-Hua Xie AU - Yong-Biao Ren AU - Hai-Song Zhou PY - 2025 JO - BMC infectious diseases DO - 10.1186/s12879-025-12064-1 UR - https://doi.org/10.1186/s12879-025-12064-1 ER -
APA
L, S., X, G., L, H., Z, G., J, L., B, Y., H, F., G, L., Y, W., Q, L., L, Y., C, L., Z, M., group, H. S., Shi, L., Li, K., Ji, M., Hu, Y., Zhou, L., Yan, X., Chen, J., Li, W., Wang, Z., Huang, Z., Zhao, Y., Li, R., Li, Y., Shi, N., Lu, Q., He, B., Wen, S., Yang, D., Liu, G., Cai, Y., Cui, W., Zheng, J., Geng, Z., Xie, Y., Ren, Y., & Zhou, H. (2025). Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.. BMC infectious diseases. https://doi.org/10.1186/s12879-025-12064-1
Source records
- pubmed · retrieved 2026-09-26T23:04:48.656Z